Remove trial restrictions Start for $1

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
McKinsey
Medtronic
Boehringer Ingelheim
Express Scripts

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR THIOGUANINE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Thioguanine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002514 ↗ Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission Completed Medical Research Council Phase 3 1993-04-01 RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well stem cell transplantation works compared to standard combination chemotherapy in treating patients with acute lymphoblastic leukemia in first remission.
NCT00002514 ↗ Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission Completed National Cancer Institute (NCI) Phase 3 1993-04-01 RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well stem cell transplantation works compared to standard combination chemotherapy in treating patients with acute lymphoblastic leukemia in first remission.
NCT00002514 ↗ Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission Completed Eastern Cooperative Oncology Group Phase 3 1993-04-01 RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with allogeneic or autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known whether stem cell transplantation is more effective than standard chemotherapy in treating acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is studying how well stem cell transplantation works compared to standard combination chemotherapy in treating patients with acute lymphoblastic leukemia in first remission.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Thioguanine

Condition Name

Condition Name for Thioguanine
Intervention Trials
Leukemia 36
Acute Lymphoblastic Leukemia 12
Untreated Childhood Acute Lymphoblastic Leukemia 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Thioguanine
Intervention Trials
Leukemia 70
Precursor Cell Lymphoblastic Leukemia-Lymphoma 63
Leukemia, Lymphoid 57
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Thioguanine

Trials by Country

Trials by Country for Thioguanine
Location Trials
Canada 166
Australia 83
New Zealand 25
Switzerland 18
Germany 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Thioguanine
Location Trials
California 42
Illinois 40
New York 40
Texas 39
Michigan 38
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Thioguanine

Clinical Trial Phase

Clinical Trial Phase for Thioguanine
Clinical Trial Phase Trials
Phase 4 6
Phase 3 47
Phase 2/Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Thioguanine
Clinical Trial Phase Trials
Completed 47
Recruiting 13
Active, not recruiting 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Thioguanine

Sponsor Name

Sponsor Name for Thioguanine
Sponsor Trials
National Cancer Institute (NCI) 40
Children's Oncology Group 26
Johann Wolfgang Goethe University Hospital 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Thioguanine
Sponsor Trials
Other 121
NIH 42
Industry 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Johnson and Johnson
Baxter
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.